Dr. Heymach Discusses the CheckMate-026 Study in Lung Cancer

John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the CheckMate-026 trial in lung cancer.

This randomized study compared frontline nivolumab (Opdivo) with chemotherapy in patients with lung cancer that had PD-L1 positivity.

Although the trial was negative, tumor mutation burden was found to be a good predictor of who was likely to derive benefit from immunotherapy as opposed to chemotherapy, says Heymach.